Cancer treatment-related neuropathic pain: proof of concept study with menthol—a TRPM8 agonist

Supportive Care in Cancer

Volumn 23, Issue 9, 2015, Pages 2769-2777

  Fallon, M T ^a   Storey, D J ^a   Krishan, A ^b   Weir, C J ^a   Mitchell, R ^a   Fleetwood Walker, S M ^a   Scott, A C ^a   Colvin, L A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer; Chemotherapy; Menthol; Neuropathic; Pain; TRPM8

Indexed keywords

ANALGESIC AGENT; MENTHOL; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; ANTINEOPLASTIC AGENT; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; TRPM8 PROTEIN, HUMAN;

ADULT; ARTICLE; BRIEF PAIN INVENTORY; CANCER PAIN; CANCER PATIENT; CANCER SURVIVOR; CANCER THERAPY; CATASTROPHIZING; CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN; CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY; CONTROLLED STUDY; CREAM; DRUG WITHDRAWAL; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROPATHIC PAIN; NOCICEPTION; PAIN INTENSITY; PAIN SEVERITY; PAIN THRESHOLD; PRIORITY JOURNAL; QUALITY OF LIFE; SENSORY NERVE CELL; SKIN FUNCTION; SKIN SENSATION; TEMPORAL SUMMATION; WALKING; AGED; AGONISTS; CHEMICALLY INDUCED; NEOPLASMS; NEURALGIA; PSYCHOLOGY; QUESTIONNAIRE; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MENTHOL; MIDDLE AGED; NEOPLASMS; NEURALGIA; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; TRPM CATION CHANNELS; YOUNG ADULT;

EID: 84938414482     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2642-8     Document Type: Article

References (45)

1. Jensen MP, Chodroff MJ, Dworkin RH (2007) The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 68(15):1178–1182
2. Torrance N, Smith BH, Bennett MI et al (2006) The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 7:281–289
3. Doth AH, Hansson PT, Jensen MP et al (2010) The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain 149(2):338–344
4. Toth C, Lander J, Wiebe S (2009) The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Med 10(5):918–929
5. Cavaletti G, Alberti P, Frigeni B et al (2011) Chemotherapy-induced neuropathy. Curr Treat Options Neurol 13:180–190
6. Naleschinski D, Baron R, Miaskowski C (2012) Identification and treatment of neuropathic pain in patients with cancer. Pain Clin Updat 20(2):1–5
7. Storey D, Sakala M, McLean C et al (2010) Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy? Ann Oncol 21:1657–1661
8. Argyriou AA, Polychronopoulos P, Iconomou G et al (2008) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34:368–377
9. Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682–1691
10. Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113–3120
11. Kehlet H, Jensen TS, Woolf CJ (2006) Persistent postsurgical pain: risk factors and prevention. Lancet 367:1618–1625
12. Gärtner R, Jensen M, Nielsen et al (2009) Prevalence of and factors associated with persistent pain following breast cancer surgery. J Am Med Assoc 302(18):1985–1992
13. Sheridan D, Foo I, O'shea H et al (2012) Long term follow up of pain and emotional characteristics of women after surgery for breast cancer. J Pain Symptom Manag 44(4):608–614
14. Haanpaa M, Attal N, Backonja M et al (2011) NeuPSIG guidelines on neuropathic pain assessment. Pain 152:4–27
15. Cruccu G, Sommer C, Anand P et al (2010) EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol 17:1010–1018
16. Smith BH, Macfarlane GJ, Torrance N (2007) Epidemiology of chronic pain, from the laboratory to the bus stop: time to add understanding of biological mechanisms to the study of risk factors in population-based research? Pain 127:5–10
17. Attal N, Bouhassira D, Baron R et al (2011) Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur J Pain 15:441–443
18. Dworkin RH, Turk DC, Katz NP et al (2011) Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION. Pain 152:S107–S115
19. Selph S, Carson S, Fu R, Thakurta S et al (2011) Drug class review: neuropathic pain. Update 1 final report. Prepared by the Oregon Evidence-based Practice Center for the Drug Effectiveness Review Project. Oregon Health and Science University, Portland
20. Liu Y, Qin N (2011) TRPM8 in health and disease: cold sensing and beyond. Adv Exp Med Biol 704:185–208
21. Eid SR, Cortright DN (2009) Transient receptor potential channels on sensory nerves. Handb Exp Pharmacol 194:261–281
22. Proudfoot CJ, Garry EM, Cottrell DF et al (2006) Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr Biol 16:1591–1605
23. Colvin LA, Johnson PR, Mitchell R et al (2008) From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol. J Clin Oncol 26:4519–4520
24. Storey DJ, Colvin LA, MacKean MJ et al (2010) Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery. J Pain Symptom Manag 39(6):e2–e4
25. Dworkin RH, Turk DC, Peirce-Sandner S et al (2010) Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 149:177–193
26. Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 23:129–138
27. Zigmond AS, Snaith RP, Zigmond AS et al (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370
28. Sullivan M (1995) The Pain Catastrophizing scale: development and validation. Psychol Assess 7:524–532
29. Bennett M (2001) The LANSS pain scale: the leeds assessment of neuropathic symptoms and signs. Pain 92:147–157
30. van Uden CJ, Besser MP (2004) Test-retest reliability of temporal and spatial gait characteristics measured with an instrumented walkway system (GAITRite). BMC Musculoskelet Disord 5:13
31. Ruff RM, Marshall LF, Crouch J et al (1993) Predictors of outcome following severe head trauma: follow-up data from the Traumatic Coma Data Bank. Brain Inj 7:101–111
32. Schmidt SL, Oliveira RM, Rocha FR et al (2000) Influences of handedness and gender on the grooved pegboard test. Brain Cogn 44:445–454
33. Scott AC, McConnell S, Laird B et al (2002) Quantitative Sensory Testing to assess the sensory characteristics of cancer-induced bone pain after radiotherapy and potential clinical biomarkers of response. Eur J Pain 16:123–133
34. Rolke R, Baron R, Maier C et al (2006) Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. [erratum appears in Pain. 2006 Nov;125(1-2):197]. Pain 123:231–243
35. Moore RA, Derry S, McQuay HJ et al (2010) Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain 149:173–176
36. Wright A (1870) Oil of peppermint as a local anaesthetic. Lancet 2464:726
37. Patapoutian A, Tate S, Woolf CJ (2009) Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov 8(1):55–68
38. Moran M, McAlexander MA, Biro T et al (2011) Targeting receptor potential channels as therapeutic targets. Nat Rev Drug Discov 10:601–620
39. Karashima Y, Damann N, Prenen J et al (2007) Bimodal action of menthol on the transient receptor potential channel TRPA1. J Neurosci 27(37):9874–9884
40. Gaudioso C, Hao J, Martin-Eauclaire MF et al (2012) Menthol pain relief through cumulative inactivation of voltage-gated sodium channels. Pain 153(2):473–484
41. Wasner G, Schattschneider J, Binder A, Baron R (2004) Topical menthol—a human model for cold pain by activation and sensitization of C nociceptors. Brain 127(Pt 5):1159–1171
42. Higashi Y, Kiuchi T, Furuta K (2010) Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain: a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Clin Ther 32(1):34–43
43. Borhani Haghighi A, Motazedian S, Rezaii R et al (2010) Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study. Int J Clin Pract 64(4):451–456
44. Ford AC, Talley NJ, Spiegel BM et al (2008) Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337:a2313
45. Baron R, Binder A, Wasner G (2010) Neuropathic pain: assessment, understanding and treatment. Lancet Neurol 9:807–819